Abstract
Bone scintigraphy is often performed to assess the response to systemic therapy of bone metastasis from prostate cancer. We examined the changes in bone scintigraphic findings and the agreement with AIP, AcP, or other tumor markers measured in the follow-up of patients with known bone metastasis after hormonal therapy. Out of 32 patients, 22 (69%) showed improved scintigraphic findings on the first follow-up bone scintigraphy after hormonal therapy. However, 7 out of 22 patients who showed improvement on the first follow-up scintigraphy, deteriorated thereafter. Changes in the scintigraphic findings were closely correlated with those in the measured tumor markers except for patients with small bone metastasis. Though there were no significant differences in the agreement ratios of the 6 tumor markers evaluated, AIP might be a practical and acceptable indicator. Bone X-ray findings did not change at all in almost half of the cases though the scintigraphic findings showed improvement or deterioration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McNeil BJ. Value of bone scanning in neoplastic disease.Semin Nucl Med 14: 277–286, 1984.
Pauwels EK, Schutte HE, Arndt JW, Langevelde AV. Scintigraphic detection of bone metastases.In Nuclear Medicine in Clinical Oncology, Winkler C (ed.), Berlin, Springer-Verlag, pp. 115–121, 1986.
McKillop JH. Bone scanning in metastatic disease.In Bone Scanning in Clinical Practice, Fogelman I (ed.), Berlin, Springer-Verlag, pp. 41–60, 1987.
Pollen JJ, Gerber K, Ashburn WL, Schmidt JD. Nuclear bone imaging in metastatic cancer of the prostate.Cancer 47: 2585–2594, 1981.
Fitzpatrick JM, Constable AR, Sherwood T, Stephenson JJ, Chisholm GD, O’Donoghue EPN. Serial bone scanning: The assessment of treatment response in carcinoma of the prostate.Br J Urol 50: 555–561, 1978.
Aizawa T, Itoh T, Tsujino S, Namiki K, Miki M. Relation between serum PAP and bone scintigraphy in prostatic cancer.KAKU IGAKU (Jpn J Nucl Med) 29: 1277–1283, 1992 (in Japanese).
Kida T, Higuchi Y. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and PAP in blood by PAP RIA kit “EIKEN.”KAKU IGAKU (Jpn J Nucl Med) 18: 907–915, 1981 (in Japanese).
Huben RP, Schellhammer PF. The role of routine follow-up bone scans after definitive therapy of localized prostatic cancer.J Urol 128: 510–512, 1982.
Chybowski FM, Larson-Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters.J Urol 145: 313–318, 1991.
Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.Urology 37: 418–422, 1991.
Merrick MV, Ding CL, Chisholm GD, Elton RA. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.BrJ Urol 57: 715–720, 1985.
Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone, scan in metastatic prostate cancer.AJR 142: 773–776, 1984.
Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer: An association with scintigraphic “flare” on bone scan.Clin Nucl Med 15: 485–487, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koizumi, K., Uchiyama, G. & Komatsu, H. Scintigraphic changes in bone metastasis from prostate cancer after hormonal therapy—Comparison with tumor markers and bone X-ray. Ann Nucl Med 8, 225–230 (1994). https://doi.org/10.1007/BF03165024
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03165024